TELAVANT

Telavant, a Roivant company, is developing innovative therapies to help patients living with inflammatory and fibrotic diseases... We are developing RVT-3101 as a potential best-in-class and first-in-class subcutaneous therapy in ulcerative colitis and Crohn's disease, including for patients with a prospectively defined biomarker who may benefit from a precision approach utilizing RVT-3101.

Also known as: Telavant, Inc.

Primary location: New York United States